FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANG
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 1

GES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Plovanic William J.					2. Issuer Name and Ticker or Trading Symbol OBALON THERAPEUTICS INC OBLN								Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Piovali	IC WIIIIdi.	<u>II J.</u>												X Directo	or		10% Ow	ner
(Last)	(F	irst)	(Middle)		3. [Date of Earliest Transaction (Month/Day/Year)								X Officer below)	(give title		Other (s below)	pecify
C/O OBALON THERAPEUTICS, INC.					10	10/25/2019								President & CEO				
5421 AV	ENIDA EN	ICINAS, SUITE	F															
					– 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) CARLSBAD CA 92008													Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)											Persor	1		·	
		Tab	le I - Noi	n-Deri	vativ	e Se	curities	Ac	quired, D	isp	osed o	f, or Be	neficial	y Owned	l			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				ear)	Execution if any	A. Deemed xecution Date, any //onth/Day/Year)				ties Acquire d Of (D) (Ins		Beneficia Owned F	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	,	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
		-							uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transact Code (Ins				Expiration D	s. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	s Silly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.75	10/25/2019			A		10,000		(1)	10)/25/2029	Common Stock	10,000	\$0	10,000	0	D	

Explanation of Responses:

1. The Option shall vest as to (i) 25% of the shares of Common Stock underlying the Stock Option on October 19, 2020 and (ii) 1/48th of the shares of Common Stock underlying the Stock Option on each monthly anniversary of October 19, 2020 thereafter, subject to the grantee's continued service with the Company through the applicable vesting date.

Remarks:

/s/ Nooshin Hussainy as 10/28/2019 attorney-in-fact for William J. Plovanic

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.